{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:25Z","timestamp":1787027905465,"version":"build-2736575974"},"reference-count":51,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Despite significant advancements in the treatment of acute myeloid leukemia (AML), hematopoietic stem cell transplantation (HSCT) remains the only curative option for patients with primary refractory AML, those with relapsed disease and for patients who are in first complete remission where the disease has high risk cytogenetic and\/or molecular features that increase relapse risk [...]<\/jats:p>","DOI":"10.3390\/curroncol32070381","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T04:04:22Z","timestamp":1751342662000},"page":"381","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Comparison of Radiation and Alkylator-Based Conditioning Therapy Regimens for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Clinician\u2019s Perspective"],"prefix":"10.3390","volume":"32","author":[{"given":"Alejandro","family":"Marinos Velarde","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Alvarenga Thiebaud","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9573-2690","authenticated-orcid":false,"given":"Yazan","family":"Madanat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Toor","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.14694\/EdBook_AM.2014.34.e327","article-title":"Indications for allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the genomic era","volume":"34","author":"Appelbaum","year":"2014","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0301-472X(03)00229-7","article-title":"Aims of conditioning","volume":"31","author":"Vriesendorp","year":"2003","journal-title":"Exp. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: Working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transpl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bmt.1702385","article-title":"Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): Report of a workshop of the European group for Blood and Marrow Transplantation (EBMT)","volume":"25","author":"Bacigalupo","year":"2000","journal-title":"Bone Marrow Transpl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: A study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41409-023-02139-5","article-title":"Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation","volume":"59","author":"Spyridonidis","year":"2024","journal-title":"Bone Marrow Transpl."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e138740","DOI":"10.1172\/JCI138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"J. Clin. Invest."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2018.04.071","article-title":"Total Body Irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"101","author":"Wong","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0360-3016(82)90083-9","article-title":"Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation","volume":"8","author":"Thomas","year":"1982","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijrobp.2012.03.033","article-title":"Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"85","author":"Wong","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.1988.6.4.576","article-title":"High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia","volume":"6","author":"Riddell","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1013.e1","DOI":"10.1016\/j.jtct.2024.08.005","article-title":"Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation","volume":"30","author":"Arslan","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41409-022-01865-6","article-title":"Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: A systematic review and network meta-analysis","volume":"58","author":"Luo","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.bbmt.2019.08.012","article-title":"Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation","volume":"25","author":"Sabloff","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_18","first-page":"71","article-title":"CT-based analysis of dose homogeneity in total body irradiation using lateral beam","volume":"5","author":"Hui","year":"2004","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.31976","article-title":"Obesity and cancer treatment efficacy: Existing challenges and opportunities","volume":"125","author":"Ross","year":"2019","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wong, J.Y.C., Liu, A., Han, C., Dandapani, S., Schultheiss, T., Palmer, J., Yang, D., Somlo, G., Salhotra, A., and Hui, S. (2022). Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation\u2014a single institution experience review. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1003908"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1182\/bloodadvances.2022007264","article-title":"Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide","volume":"6","author":"Palmer","year":"2022","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbmt.2017.01.067","article-title":"Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed\/Refractory Acute Leukemia","volume":"23","author":"Stein","year":"2017","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"368.e1","DOI":"10.1016\/j.jtct.2022.03.025","article-title":"Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission","volume":"28","author":"Stein","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood-2024-203492","article-title":"Safety of 20Gy Total Marrow Irradiation Based Conditioning Regimen for Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy","volume":"144","author":"Zorutti","year":"2024","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: One size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen","volume":"70","author":"Tutschka","year":"1987","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"Couriel","year":"2004","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/bmt.2015.238","article-title":"Busulfan fludarabine vs. busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: Systematic review and meta-analysis","volume":"51","author":"Cohen","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JCO.2011.40.2362","article-title":"Randomized trial of myeloablative conditioning regimens: Busulfan plus cyclophosphamide versus busulfan plus fludarabine","volume":"31","author":"Lee","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"52","author":"Andersson","year":"2017","journal-title":"Bone Marrow Transpl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00007691-199810000-00017","article-title":"Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation","volume":"20","author":"Slattery","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e069901e","DOI":"10.1097\/01.HS9.0000971968.06990.1e","article-title":"P1270: Myeloablative Fractionated Busulfan-Based Conditioning Regimen in Patients with AML and MDS: Results of a Randomized Clinical Trial Comparing 2 Fractionation Schedules","volume":"7","author":"Popat","year":"2023","journal-title":"HemaSphere"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1182\/bloodadvances.2023010850","article-title":"Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities","volume":"7","author":"Popat","year":"2023","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5144\/1658-3876.2011.17","article-title":"Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: A systematic review and meta-analysis","volume":"4","author":"Gupta","year":"2011","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.bmt.1701334","article-title":"Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan\/cyclophosphamide vs. total body irradiation: A meta-analysis","volume":"22","author":"Hartman","year":"1998","journal-title":"Bone Marrow Transpl."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1080\/10428194.2020.1789621","article-title":"Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A single-center experience","volume":"61","author":"Zhao","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2006.11.024","article-title":"Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan","volume":"13","author":"Oran","year":"2007","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transpl."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/bloodadvances.2019001266","article-title":"Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs. busulfan-based regimens: A CIBMTR report","volume":"4","author":"Zhou","year":"2020","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood.2019003662","article-title":"Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?","volume":"135","author":"Ciurea","year":"2020","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","article-title":"Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: A prospective, open-label randomised phase 3 trial","volume":"13","author":"Kienast","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)","volume":"35","author":"Iacobelli","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/sj.leu.2403770","article-title":"The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: A donor vs. no donor comparison","volume":"19","author":"Mohty","year":"2005","journal-title":"Leukemia"},{"key":"ref_47","first-page":"e28","article-title":"Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): A randomised, non-inferiority, phase 3 trial. The Lancet","volume":"7","author":"Beelen","year":"2020","journal-title":"Haematology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/JCO.23.02018","article-title":"Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed\/Refractory AML","volume":"43","author":"Gyurkocza","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ijrobp.2024.07.160","article-title":"Phase II Trial of TMLI 20 Gy in Combination with Cyclophosphamide and Etoposide in Patients with Poor-Risk Acute Leukemia","volume":"120","author":"Wong","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): A randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-024-01060-4","article-title":"Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: An EBMT registry analysis of 1540 patients","volume":"14","author":"Ngoya","year":"2024","journal-title":"Blood Cancer J."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/381\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:02:07Z","timestamp":1760032927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":51,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["curroncol32070381"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32070381","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}